Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Porcine endogenous retrovirus (PERV) refers to retroviral sequences of the gammaretrovirus genus that are naturally integrated into the genome of pigs as part of their DNA. PERVs are present in all pigs and exist mainly in a non-infectious, genomic (provirus) form, but some variants (notably PERV-A and PERV-B, and certain recombinants involving PERV-C) can produce infectious viruses capable of infecting human cells in vitro. Their presence raises safety concerns for xenotransplantation, as there is theoretical risk that PERV could transmit from pig tissue to human recipients and potentially cause zoonotic infection, although no clinical human infection has been documented. Research efforts include inactivation of PERV by genome editing (e.g., CRISPR-Cas9), RNA interference, and breeding strategies to minimize risk[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Porcine endogenous retrovirus (PERV).